Bacterial cytosol lacks the compartmentalized buffering characteristic of eukaryotic cells and instead constitutes a highly crowded, strongly interacting molecular environment. During co-translational and post-translational stages, nascent polypeptides experience prolonged exposure of hydrophobic segments, a large conformational search space, and multiple folding pathways, making them prone to misfolding and non-specific aggregation. These events can result in loss of activity, formation of toxic aggregates, and global disruption of proteostasis. Molecular chaperones are protein factors that do not become part of the final product structure, yet provide process-level assurance for protein folding, assembly, trafficking, remodeling, and stress recovery. In bacteria, canonical chaperone modules include trigger factor (TF), the DnaK-DnaJ-GrpE system, the GroEL/GroES system, and HtpG. Through substrate recognition, ATP-driven binding–release cycles, and encapsulated folding in isolation chambers, these modules form a cooperative network that performs relay-like quality control on folding-challenged substrates. This article focuses on the organizational logic and representative mechanisms of bacterial chaperone networks, and further discusses the functional diversity revealed by multi-copy chaperone systems in myxobacteria and related taxa, as well as their potential value for engineering applications.
Keywords: molecular chaperones; protein folding; proteostasis; co-translational folding; DnaK; GroEL; HtpG; myxobacteria
I. Intracellular Folding Environment in Bacteria and the Rationale for Molecular Chaperones
1.1 Structural pressures imposed by a crowded cytosol
(1) Physical origins of folding risk
- As nascent polypeptides transition from linear chains to three-dimensional conformations, hydrophobic cores have not yet formed; exposure of hydrophobic segments increases intermolecular attraction and markedly elevates aggregation risk.
- Macromolecular crowding increases effective concentration and collision frequency, making weak reversible interactions more likely to convert into irreversible aggregation.
- Segment-by-segment emergence during co-translation enriches folding intermediates; once a local misfolded conformation forms, it may become “locked in” as subsequent segments are added.
(2) System-level consequences of misfolding
- At the individual-protein level, outcomes include inactivation, increased degradation susceptibility, or formation of inclusion body–like aggregates.
- At the network level, chaperone load increases and degradation pathways can become overloaded, reducing overall proteostasis capacity.
- At the physiological level, stress responses such as the heat-shock response may be triggered, affecting growth rate and environmental adaptability.
1.2 Functional boundaries and operational objectives of molecular chaperones
(1) Definition and boundaries
- The core task of molecular chaperones is not to “encode folding information,” but to reduce the probability of incorrect pathways and increase the success rate of correct folding.
- Chaperones typically bind substrates reversibly and transiently, dissociating once native conformations are achieved, thereby avoiding incorporation into the final product structure.
(2) Typical implementation routes
- Recognition and temporary shielding of hydrophobic segments to reduce non-specific interactions.
- ATP-driven conformational cycling that enables repeatable “capture–stabilize–release” processes, providing multiple refolding attempts.
- Use of isolation chambers or semi-enclosed spaces to separate single-molecule substrates from the crowded environment, strongly suppressing aggregation and improving folding trajectories.
II. Organizational Logic of Bacterial Chaperone Networks
2.1 Modular division of labor and relay-like quality control
(1) A functional chain of front-end, hub, and terminal modules
- The front-end module, typified by TF, resides at the ribosomal exit tunnel and prioritizes nascent chains during co-translation.
- The hub module, centered on the DnaK system, has broad substrate scope and high plasticity, performing widespread stabilization and remodeling while coordinating with other modules.
- The terminal module, typified by GroEL/GroES, provides an isolated folding chamber for complex substrates and often serves as a key pathway for difficult-to-fold proteins.
(2) Fate routing of folding-failed substrates
- If substrates remain non-compliant after multiple chaperone cycles, cells typically allocate resources between continued remodeling and targeting for degradation.
- Routing decisions depend on stress intensity, substrate importance, chaperone load, and metabolic state, and ultimately shape global proteostasis.
2.2 The core of synergy: substrate transfer and coupling to chaperone cycles
(1) Logic of substrate transfer
- Between TF and DnaK, handoff commonly reflects a shift from “early anti-aggregation” to “mid-stage remodeling,” preventing early commitment to irreversible aggregation.
- Between DnaK and GroEL, transfer reflects escalation from “general stabilization/local remodeling” to “isolated folding chamber,” particularly for domain-complex or highly aggregation-prone substrates.
(2) System-level meaning of ATP cycling
- ATP drives conformational changes of individual chaperones and, at the network level, determines throughput and response speed.
- Under high expression or stress, ATP supply and chaperone expression regulation jointly define the proteostasis ceiling, manifesting as an “energy–quality control” coupling constraint.
III. Mechanistic Analysis of Representative Chaperone Systems
3.1 TF: a nascent-chain protection factor at the ribosomal exit
(1) Spatial localization and substrate capture
- TF localizes near the ribosomal polypeptide exit, enabling contact and protection as soon as the nascent chain emerges.
- This confers a temporal advantage and shortens the unprotected exposure window for hydrophobic segments.
(2) Early shaping of folding pathways
- TF primarily suppresses early aggregation and promotes local structure formation, generating intermediates that remain competent for downstream folding.
- Substrates not matured at the TF stage are typically handed off to downstream chaperone systems to avoid prolonged cytosolic residence and aggregation.
3.2 The DnaK-DnaJ-GrpE system: a general hub and dynamic remodeling platform
(1) ATP-driven capture–release cycling
- DnaK switches substrate affinity via nucleotide-dependent states, enabling reversible capture and release and providing multiple rounds of conformational searching.
- This cycle both prevents aggregation and “loosens” non-native conformations, promoting rearrangement toward productive states.
(2) Fine kinetic control by co-chaperones
- DnaJ promotes substrate delivery and stimulates ATP hydrolysis, improving capture efficiency and stabilizing capacity.
- GrpE promotes nucleotide exchange, accelerating substrate release and cycle reset, increasing throughput while preventing prolonged substrate sequestration.
(3) Hub properties within the network
- DnaK accepts substrates not completed by TF and can route more complex substrates to GroEL for further processing.
- During stress recovery, DnaK cooperates with other remodeling factors to reactivate aggregated proteins, making it a key node in proteostasis maintenance.
3.3 The GroEL/GroES system: an isolated folding chamber for difficult substrates
(1) Barrel architecture and encapsulated folding
- GroEL provides a central cavity that accommodates single-molecule non-native substrates, markedly reducing intermolecular aggregation probability.
- GroES functions as a lid to close the cavity, allowing substrates to attempt folding in a relatively isolated environment with reduced external interference.
(2) A “time-window” folding cycle
- ATP-driven GroEL conformational switching defines substrate residence time in the cavity, making folding a repeatable, periodic process.
- If native conformation is not achieved within one window, substrates may re-enter subsequent cycles after release or be routed to alternative fates.
3.4 HtpG: remodeling and functional recovery of metastable substrates
(1) Dimeric architecture and client recognition
- HtpG typically operates as a dimer, forming a platform that can engage exposed hydrophobic interfaces on client proteins.
- It preferentially handles metastable or highly fluctuating substrates, suppressing aggregation and promoting return to active conformations through “remodeling activation.”
(2) Synergy with other modules
- During stress recovery and remodeling, HtpG often complements systems such as DnaK, improving recovery efficiency.
- Under multi-module cooperation, HtpG functions more as a “remodeling accelerator” than as a primary pathway that completes full folding independently.
IV. Significance of Multi-Copy Chaperone Systems in Myxobacteria
4.1 Multicellular behaviors and the demand for proteostasis capacity
(1) Proteostasis pressure driven by physiological complexity
- Myxobacteria exhibit social motility, cooperative predation, and aggregation-based development under nutrient limitation, with large amplitude changes in expression programs across the life cycle.
- Developmental differentiation and secondary metabolism often involve large enzyme systems and multi-component complexes, imposing higher demands on folding, assembly, and quality control.
(2) Expansion of copies and variants
- Myxobacteria often have large genomes and many duplicated genes; chaperone families can exhibit multiple copies and non-canonical variants.
- Multi-copy architectures provide a structural basis for broadened substrate scope, stage-specific regulation, and specialized division of labor, potentially expanding the strategy space for proteostasis control.
4.2 Engineering implications
(1) Differentiated expansion of the chaperone toolbox
- Multi-copy variants may differ in substrate preference, kinetic parameters, and cooperative relationships, providing more selectable modules for improving soluble expression of difficult proteins.
- Compared with overexpressing a single chaperone, systematic screening based on “substrate type–chaperone combination–expression level” is more likely to yield reproducible improvements.
(2) Modular proteostasis design in synthetic biology
- Treating chaperone systems as tunable proteostasis components enables co-design with translation rate, promoter strength, secretion pathways, and degradation pathways to couple yield optimization with quality control.
- Metabolic burden and growth inhibition risks must be assessed concurrently to avoid trading substantial growth and productivity losses for solubility gains.
V. Aladdin-Related Products
Catalog No. | Product Name | Specification or Purity | Type | Target | Use |
HSP70/DnaK substrate peptide | -- | Peptide (substrate peptide) | Hsp70/DnaK | Substrate peptide for Hsp70/DnaK binding/competition assays and ATPase/chaperone-activity readouts; supports mechanistic studies and method validation (e.g., substrate occupancy and modulation effects) | |
Hsp60 Mouse mAb | Validated, High performance, Carrier Free, Azide Free, ≥95%(SDS-PAGE), 1.0 mg/mL | Antibody | Hsp60 | Detection of Hsp60 expression/localization/abundance to support folding and proteostasis studies | |
Hsp60 Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA | Antibody | Hsp60 | Routine detection/validation of Hsp60 chaperone signals in chaperone-related assays | |
Hsp60 Mouse mAb (AF405) | ExactAb™, Validated, 0.5 mg/mL | Fluorescent antibody | Hsp60 | Fluorescence-based detection/localization of Hsp60; supports mapping stress-associated redistribution | |
Hsp60 Mouse mAb (AF700) | ExactAb™, Validated, 0.5 mg/mL | Fluorescent antibody | Hsp60 | Fluorescence-based detection/localization of Hsp60; supports multicolor readout of chaperone signals | |
Hsp70 Mouse mAb | ExactAb™, Validated, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), 1.0 mg/mL | Antibody | Hsp70 | Detection of Hsp70 (common marker in heat-shock/stress response and proteostasis studies) | |
Hsp70 Mouse mAb | ExactAb™, Validated, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), 1.0 mg/mL | Antibody | Hsp70 | Detection of Hsp70; supports monitoring chaperone network activity and stress-induced changes | |
Hsp70 Mouse mAb | Carrier Free, ExactAb™, Azide Free, Validated, High Performance, See COA | Antibody | Hsp70 | Routine detection/validation of Hsp70 in chaperone-related workflows | |
Hsp70 Mouse mAb | ExactAb™, Validated, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE), 1.0 mg/mL | Antibody | Hsp70 | Detection of Hsp70 expression/localization and dynamic regulation | |
Hsp70 Mouse mAb (Biotin) | Azide Free, Validated, High Performance, ExactAb™, 0.5 mg/mL | Biotinylated antibody | Hsp70 | Capture/enrichment/detection of Hsp70; supports chaperone complex and interaction-network studies | |
Recombinant Hsp90 alpha Antibody | ExactAb™, Validated, Recombinant, High performance, 1.0 mg/mL | Recombinant antibody | Hsp90α | Detection of Hsp90α; supports studies of chaperone-dependent processes and client proteostasis changes | |
Recombinant Hsp90 Antibody | Recombinant, ExactAb™, Validated, See COA | Recombinant antibody | Hsp90 | Detection of Hsp90; supports baseline readouts in chaperone network/proteostasis studies | |
HSP70-IN-1 | 10mM in DMSO | Small-molecule inhibitor | Hsp70 | Chemical inhibition of Hsp70 to probe chaperone dependence in folding, stress response, and proteostasis | |
HSP70-IN-6 | -- | Small-molecule inhibitor | Hsp70 | Perturbation of Hsp70-related processes to support mechanism/phenotype dissection | |
Hsp70-derived octapeptide | ≥98% | Peptide | Hsp70 | Tool peptide for chaperone structure/epitope/interaction studies or model-substrate method validation | |
AT13387 | ≥98% | Small-molecule inhibitor | Hsp90 | Inhibition of Hsp90 to study client maturation/stability and pathway regulation | |
Geldanamycin from Streptomyces hygroscopicus | Moligand™, ≥98%(HPLC) | Small-molecule inhibitor | Hsp90 | Classic Hsp90 inhibitor for perturbing chaperone function and client proteostasis | |
17-AAG | ≥98% | Small-molecule inhibitor | Hsp90 | Hsp90 inhibition for functional perturbation and client dependence validation | |
Radicicol | ≥98% | Small-molecule inhibitor | Hsp90 | Hsp90 inhibition to study Hsp90-mediated proteostasis and chaperone dependence | |
Ganetespib (STA-9090) | ≥98% | Small-molecule inhibitor | Hsp90 | Hsp90 inhibition to study chaperone-dependent signaling and client stability changes | |
Debio 0932 | ≥99% | Small-molecule inhibitor | Chaperone-related (see product information) | Chemical perturbation of chaperone pathways (target/mechanism per product information) | |
KBU2046 | ≥98% | Small-molecule modulator | Chaperone-related (see product information) | Modulation of chaperone-related proteostasis/functional regulation (target/mechanism per product information) | |
HSP90-IN-9 | -- | Small-molecule inhibitor | Hsp90 | Inhibition of Hsp90-associated processes to support chaperone-dependence studies | |
HSP90-IN-30 | -- | Small-molecule inhibitor | Hsp90 | Perturbation of Hsp90 function; supports readouts of client proteostasis changes and pathway responses | |
Tanespimycin (17-AAG) | 10mM in DMSO | Small-molecule inhibitor | Hsp90 | Pre-dosed inhibitor for rapid perturbation of Hsp90 function and client maturation/stability studies | |
p5 Ligand for Dnak and DnaJ | -- | Ligand/peptide | DnaK/DnaJ (bacterial chaperone system) | Binding/regulation studies for bacterial DnaK/DnaJ; supports interaction-mechanism research | |
VER-155008 | Moligand™, ≥98%(HPLC) | Small-molecule inhibitor | Hsp70 | Hsp70 inhibition to study folding, stress adaptation, and proteostasis regulation | |
JG98 | ≥99% | Small-molecule inhibitor | Hsp70-related (see product information) | Perturbation of Hsp70 system–associated processes (interaction/functional regulation) for mechanistic studies | |
TKD Peptide (Hsp70 Peptide) | ≥98% | Peptide | Hsp70 | Functional/tool peptide for chaperone-related mechanism studies and assay construction | |
KNK 437 (Heat Shock Protein Inhibitor I) | 10mM in DMSO | Small-molecule inhibitor | Heat-shock response / chaperone induction | Inhibits stress-induced chaperone expression; enables analysis at the expression-regulation level | |
Geldanamycin (NSC 122750) | Moligand™, 10mM in DMSO | Small-molecule inhibitor | Hsp90 | Pre-dosed solution for rapid chaperone-pathway perturbation experiments | |
Geldanamycin-FITC | ≥98%(HPLC), from Streptomyces hygroscopicus | Fluorescent probe/inhibitor | Hsp90 | Probe-like tool for binding studies, tracing, or method development in chaperone research | |
Geldanamycin-biotin | ≥98% | Biotinylated probe/inhibitor | Hsp90 | Capture/enrichment of Hsp90 and complexes; supports interaction-network studies | |
NVP-AUY922 | Moligand™, ≥98% | Small-molecule inhibitor | Hsp90 | Hsp90 inhibition for perturbing Hsp90 function and client-protein proteostasis studies | |
Luminespib (NVP-AUY922) | Moligand™, 10mM in DMSO | Small-molecule inhibitor | Hsp90 | Pre-dosed solution for rapid perturbation experiments in chaperone-related pathways |
Molecular chaperone systems constitute core infrastructure for bacterial protein quality control. Their value lies not in replacing intrinsic folding information of proteins, but in creating feasible pathways to correct folding by suppressing aggregation, providing isolated folding environments, and implementing ATP-driven dynamic remodeling. TF, the DnaK system, the GroEL/GroES system, and HtpG form a hierarchical and highly cooperative network that enables cells to maintain proteostasis under both routine physiology and stress perturbations. For both research and application, understanding relay-like processing logic and optimizing chaperone combinations is typically superior to intensifying a single node; moreover, the variant resources and functional specialization exhibited by multi-copy chaperone systems in myxobacteria and related taxa represent an important direction for discovering new proteostasis control mechanisms and developing chaperone toolsets with improved fit for engineering needs.
Aladdin: https://www.aladdinsci.com/